NCT01662505

Volasertib in Japanese Patients With Acute Myeloid Leukemia (AML)

An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 19 (actual)
• Sponsor: Boehringer Ingelheim · Industry
• Sex: All
• Age: 18 Years – 99 Years
• Healthy volunteers: Not accepted

Summary

To investigate safety, tolerability, maximum tolerated dose of volasertib in Japanese patients with AML

Conditions

• Leukemia, Myeloid, Acute

Interventions

Type	Name	Description
DRUG	Volasertib	Patient to receive volasertib

Timeline

• Start date: 2012-08-01
• Primary completion: 2015-05-01
• Completion: 2015-05-01
• First posted: 2012-08-10
• Last updated: 2018-07-30
• Results posted: 2018-07-30

Locations

6 sites across 1 country: Japan